Employment Discrimination - Reasonable Accommodations - Disabilities Due to Childbirth, Menopause, and Related Medical Conditions
HB0536 updates Maryland law governing emergency epinephrine use by replacing the term “auto-injectable epinephrine” with “emergency use epinephrine” across education, health, and health occupations statutes. The bill broadens the definition to include not only portable disposable drug delivery devices, but also other FDA-approved products that contain a premeasured single dose of epinephrine for treating anaphylaxis in an emergency. It also renames the existing Emergency Use Auto-Injectable Epinephrine Program to the Emergency Use Epinephrine Program.
The bill makes conforming changes to school, youth camp, higher education, and naturopathic medicine provisions so that schools, nonpublic schools, youth camps, participating facilities, and authorized health professionals may obtain, store, prescribe, dispense, and administer emergency use epinephrine under the updated terminology. It preserves existing requirements for training, storage, notification, reporting of incidents, and civil liability protections for good-faith responders, while maintaining exceptions for gross negligence, willful misconduct, or expired or improperly stored medication in certain settings.
HB0536 amends multiple sections of the Education Article, Health–General Article, and Health Occupations Article to modernize terminology and expand the statutory definition of epinephrine delivery products covered by Maryland’s emergency-use framework. The bill does not create a new program so much as rename and update existing programs and policies, ensuring that schools, child care providers, youth camps, and participating facilities can continue to stock and use epinephrine under current legal protections and reporting rules. It also affects prescribing and dispensing authority for physicians, pharmacists, and nurse practitioners, and it updates the naturopathic formulary provisions to reflect the new terminology.
The bill appears generally noncontroversial and technical in nature, with an emphasis on aligning state law with current FDA-approved epinephrine products and modern terminology. Because the available record contains no committee transcript or vote history, there is no documented opposition or support to assess beyond the bill’s text. The structure of the bill suggests a broad public-safety purpose focused on maintaining access to life-saving anaphylaxis treatment in schools and other public settings.
The main substantive issue is the scope of the definition change: the bill expands coverage from a specific auto-injector format to any FDA-approved emergency-use epinephrine product, which may raise implementation questions for schools, camps, and facilities about procurement, storage, training, and compliance. Another possible point of attention is the retention of liability protections and the specific exceptions tied to gross negligence, willful misconduct, improper storage, and expired medication. No explicit stakeholder objections are provided in the record, so any contention is inferred from the operational changes rather than from documented debate.